Researchers at NCI Center for Cancer Research have identified extrachromosomal DNA as a major driver of small cell lung cancer, highlighting a novel biomarker and therapeutic target that could be used to eliminate the most aggressive and shapeshifting SCLC cells. The study was published in Cancer Discovery.
Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.
